Mesoblast Limited (ASX:MSB)
Australia
· Delayed Price · Currency is AUD | Market Cap | 2.89B |
| Revenue (ttm) | 98.02M |
| Net Income (ttm) | -141.48M |
| Shares Out | 1.29B |
| EPS (ttm) | -0.11 |
| PE Ratio | n/a |
| Forward PE | 176.21 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9,596,730 |
| Average Volume | 3,102,783 |
| Open | 2.500 |
| Previous Close | 2.420 |
| Day's Range | 2.230 - 2.630 |
| 52-Week Range | 1.515 - 3.310 |
| Beta | 0.90 |
| RSI | 37.97 |
| Earnings Date | Feb 27, 2026 |
About Mesoblast
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company’s proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as ulc... [Read more]
Financial Performance
In fiscal year 2025, Mesoblast's revenue was $17.20 million, an increase of 191.39% compared to the previous year's $5.90 million. Losses were -$102.14 million, 16.1% more than in 2024.
Financial numbers in USD Financial StatementsNews
Mesoblast (MESO) Reports Significant Miss in 1H Earnings
Mesoblast (MESO) Reports Significant Miss in 1H Earnings
Mesoblast misses H1 estimates
Mesoblast Limited (MESO) Q2 2026 Earnings Call Transcript
Mesoblast Limited (MESO) Q2 2026 Earnings Call Transcript
Half Year 2026 Mesoblast Ltd Earnings Presentation Transcript
Half Year 2026 Mesoblast Ltd Earnings Presentation Transcript
Ryoncil® Profits Underpinning Substantial Growth Pipeline
Financial Results and Operational Update for Half-Year Ended December 31, 2025 Financial Results and Operational Update for Half-Year Ended December 31, 2025
What's Next: Mesoblast's Earnings Preview
Mesoblast (NASDAQ: MESO) is gearing up to announce its quarterly earnings on Thursday, 2026-02-26. Here's a quick overview of what investors should know before the release. Analysts are estimating th...
Mesoblast Financial Results and Corporate Update Webcast
NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operation...
Mesoblast Touts High Survival Rates For FDA-Approved Cell Therapy
Mesoblast Limited (NASDAQ: MESO) shares are down during Thursday’s premarket session after the company provided data presented at the Tandem Meetings of the American Society for Transplantation and C...
Mesoblast Touts High Survival Rates For FDA-Approved Cell Therapy
In a press release on Wednesday, it was noted that Ryoncil has shown high survival rates in patients with steroid-refractory acute graft versus host disease, emphasizing the need for earlier intervent...
High Survival Rates With Ryoncil® in EIND Program Emphasize Importance of Earlier Use in Both Children and Adults With SR-aGvHD
NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided data presented at the Feb...
Mesoblast: Real-World Data Validates The Bull Case For Ryoncil
Mesoblast (MESO) is demonstrating rapid revenue growth post-Ryoncil launch, with Q4 gross sales up 60% sequentially and strong market penetration. MESO's balance sheet is fortified by $130M cash and a...
Ryoncil® Net Revenues Increase for the Quarter to US$30M
NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent ...
Mesoblast Says Most Children Survive After Early Use Of FDA-Approved Cell Therapy For Organ Transplant Related Complication
Mesoblast reports early real-world data showing 84% survival in children treated with FDA-approved Ryoncil, as the company expands hospital access and prepares an adult trial. ... Full story available...
Real-World Commercial Experience with Ryoncil® Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment
NEW YORK, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on use of Ryonc...
FDA Signals Support For Mesoblast's Cell Therapy For Chronic Back Pain
On Sunday, Mesoblast Limited (NASDAQ: MESO) provided feedback received from the U.S. Food & Drug Administration (FDA) on potential filing of a Biologics License Application (BLA) for its allogeneic c...
FDA Acknowledges Effects on Pain Intensity Favor Rexlemestrocel-L, Confirms 12-Month Reduction in Back Pain Supports Product Efficacy
NEW YORK, Jan. 18, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided feedback received from th...
Mesoblast (MESO) Sees Revenue Surge and Secures $125M Loan
Mesoblast (MESO) Sees Revenue Surge and Secures $125M Loan
Mesoblast Stock Rises On Strong Year‑Over‑Year Growth In Ryoncil Sales
Mesoblast Ltd (NASDAQ: MESO) shares are trading higher on Friday after the company reported strong year‑over‑year growth in December quarter sales of its flagship therapy, Ryoncil . Mesoblast stock i...
Mesoblast Surges As Flagship Product Ryoncil Delivers Strong Quarterly Sales Growth
(RTTNews) - Shares of Mesoblast Ltd (MESO) jumped more than 8% in after-hours trading on Thursday after the company reported continued strong quarterly growth in sales of its flagship product, Ryoncil...
Ryoncil® Sales Increase 60% in December Quarter to US$35.1M
Strong Balance Sheet Reflects Revenue Growth and New $125M Five-Year Facility Strong Balance Sheet Reflects Revenue Growth and New $125M Five-Year Facility
ASX 200 LIVE: ASX trims gains; Woodside, Santos rally on oil spike, Rio down 5pc
Energy paces ASX gains as oil rallies; Rio Tinto in talks with Glencore; Codan issues profit upgrade; Mesoblast reports sales boom; TD Securities tips Februay rate hike. Follow live.
Mesoblast (MESO) Appoints New Non-Executive Chair
Mesoblast (MESO) Appoints New Non-Executive Chair
Mesoblast Chair Jane Bell To Retire; Appoints Philip Facchina As Non-executive Chair
(RTTNews) - Mesoblast Limited (MESO, MSB.AX) announced that Jane Bell will retire from her role as Chair and will remain on the Board as a non-executive director. The Board has unanimously appointed P...
Mesoblast Announces Changes to Board of Directors' Leadership Roles
NEW YORK, Jan. 01, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that as foreshadowed at ...
Mesoblast Retires Senior Debt with Non-Dilutive, Lower Cost, Five-Year Credit Line
Mesoblast has option to draw down up to US$125 million by June 30, 2026 New facility does not encumber any of Mesoblast's material assets or intellectual property NEW YORK, Dec. 29, 2025 (GLOBE NEWSWI...